ClinicalTrials.gov
ClinicalTrials.gov Menu

Stem Cell Therapy in Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02241928
Recruitment Status : Withdrawn
First Posted : September 16, 2014
Last Update Posted : October 25, 2018
Sponsor:
Information provided by (Responsible Party):
Neurogen Brain and Spine Institute

September 12, 2014
September 16, 2014
October 25, 2018
January 2009
December 2018   (Final data collection date for primary outcome measure)
Manual Muscle Testing [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT02241928 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Stem Cell Therapy in Muscular Dystrophy
Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy
The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Muscular Dystrophy
Biological: Stem Cell
Intrathecal Autologous bone marrow mononuclear cell transplantation
Experimental: Stem Cell
Bone marrow mononuclear cell transplantation
Intervention: Biological: Stem Cell
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
1000
May 2019
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age group of 6 months and above
  • muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion Criteria:

  • presence of respiratory distress
  • presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
  • malignancies
  • acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
  • pregnancy or breastfeeding
Sexes Eligible for Study: All
6 Months to 60 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT02241928
NGBSI-14
Yes
Not Provided
Not Provided
Neurogen Brain and Spine Institute
Neurogen Brain and Spine Institute
Not Provided
Not Provided
Neurogen Brain and Spine Institute
October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP